Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ModCAR CD20
- Development stage
- Preclinical
- Lead developer
- Hauul Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ModCAR CD20 is a non-viral modular chimeric antigen receptor (CAR) cell therapy being developed by Hauul Bio for the treatment of hematologic malignancies. The therapy utilizes Hauul Bio's proprietary ModCAR platform, which employs an scFv-fusion protein to recognize and target CD20-positive malignant cells. Unlike conventional viral-mediated CAR-T therapies, the ModCAR platform uses a non-viral approach to simplify manufacturing and improve safety, allowing for modular and customizable antigen targeting.
- Other names
- ModCAR-CD20ModCAR-CD-20ModCAR-CD 20
02
Targets
Beyond the preview
Go deeper on ModCAR CD20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ModCAR CD20.